Decitabine treatment for poor blood recovery after transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 3 trial tests decitabine to help people whose blood counts have not recovered well after an allogeneic stem cell transplant (allo-HSCT). It aims to improve blood production when donor cells are working, and your condition is otherwise stable enough for treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with poor graft function (PGF) at least 28 days after your transplant, and it lasted over 2 weeks
- Your transplant donor cells are fully established (full donor chimerism)
- Your original cancer or illness is in remission (not active/relapsed)
- You do not have severe or worsening graft-versus-host disease (GVHD) right now
- Your general health is good enough for treatment (ECOG 0 to 2) and you’re expected to live more than 1 month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving decitabine and donated umbilical cord blood can improve blood count recovery when a transplant is not working well. It is for people who have poor graft function at least 28 days after an allogeneic transplant and meet several safety and disease-status conditions.
This study tests whether umbilical cord blood cells can help patients whose blood counts have dropped again after a stem cell transplant. It may be an option for people who have recovered initially but later develop low blood cell levels.
This study tests whether giving extra stem cells from your original donor can help your blood cell counts recover after a transplant. It is for people whose new immune system has not fully engrafted or whose counts are dangerously low.
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
This trial studies whether adding decitabine plus chemotherapy before a stem cell transplant can better control “minimal residual disease” (very small amounts of leukemia left behind) in certain high-risk acute leukemia types. It may help reduce the chance of the leukemia coming back after transplant.
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
Hear when a new Poor Graft Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.